Editas Medicine, Inc. (EDIT) has a MoatMap StockRank of 7/100 based on Quality (10/100), Value (31/100), and Momentum (45/100) factor scores. The current signal is STRONG SELL. Editas Medicine, Inc., a US healthcare (gene editing) company, operates in a nascent and highly speculative field with immense R&D costs and unproven commercial viability. Its 'STRONG_SELL' signal and low quality score (Q:18) indicate it is far from a 'quality compounder' or 'asset-light' business. It represents a 'broken business model' or speculative venture, which the fund explicitly avoids.
Editas Medicine, Inc. is a clinical-stage biotechnology company dedicated to developing gene editing medicines using CRISPR technology to treat serious diseases. As a pioneer in CRISPR gene editing, it holds key intellectual property and collaborates strategically with pharmaceutical partners. The company is a leading player in a transformative area of genetic medicine, targeting unmet medical needs.
| Price | $2.76 |
| Market Cap | $270M |
| P/E (Forward) | -2.72 |
| Price/Book | 54.67 |
| Return on Equity | -326.1% |
| Return on Invested Capital | -109.7% |
| Debt/Equity | 392.40 |
| Gross Margin | -109.2% |
| Operating Margin | -883.2% |
| Revenue Growth | -39.2% |
| Free Cash Flow | $-74M |
Editas Medicine, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).